The influence of selected nonsteroidal anti-inflammatory drugs on antioxidative enzymes activity;Wpływ wybranych niesteroidowych leków przeciwzapalnych na aktywność enzymów antyoksydacyjnych

Polskie Archiwum Medycyny Wewnetrznej

Volumn 115, Issue 2, 2006, Pages 112-117

  Kowalczyk, Edward ^a,d   Kopff, Anna ^b   Błaszczyk, Jan ^a   Fijałkowski, Paweł ^a   Kopff, Maria ^c  

^a Zaklad Fizjol Czlowieka i Biofizyki   (Poland)

^b Klinika Kardiologii   (Poland)

^c Katedra Chemii i Biochemii Klinicznej   (Poland)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antioxidative enzymes; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CATALASE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GLUTATHIONE PEROXIDASE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; NONHUMAN; RAT; STOMACH TUBE;

EID: 33745899635     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Vane J.R. Inhibition of prostaglandin synthesis as a mechanizm of action for aspiryn-like drugs. Nature New Biol. 1971; 231: 232.
2. Williams C.S., Du Bois R.N. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol. 1996; 270: G393.
3. Masferrer J.L., Zweifel B.S., Seibert K., Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest. 1990; 86: 1375.
4. Gierse J.K., Hauser S.D., Creely D.P. i wsp. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase II. J Biochem. 1995; 305: 479.
5. Xie W.L., Chipman J.G., Robertson D.L., Erikson R.L., Simmons D.L. Expresssion of a mitogen-responsive gene encoding prostaglandin synthase is a regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991; 88: 2692.
6. Kujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., Herschman H.R. TIS10, a phorbol ester tumor promoter - inducible m-RNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue 1. J Biol Chem. 1991; 266: 12866.
7. Smith W.L. Prostanoid bio-synthesis and the mechanism of action. Am J Physiol. 1992; 263: F118.
8. Morita I., Schindler M., Regier M.K. i wsp Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem. 1993; 270: 10902.
9. Rehman Q., Sack K.E. Kiedy stosować wybiórcze inhibitory COX-2. Medycyna Po Dyplomie 2000; 9: 54.
10. Dreser H. Pharmakologisches ubek Aspiryn (acetylsalicylsaure). Pfluger's Arch. 1899, 76, 306. cyt. za Awtry E.N., Loscalzo J.: Aspiryn Circulation. 2000; 101: 1206.
11. cyt. za Awtry E.N., Loscalzo J.: Aspiryn Circulation. 2000; 101: 1206
12. Weiss H.J., Aledort L.M. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet. 1967; 2: 495.
13. Roth G.J., Majerus P.W. The mechanism of the effect of aspirin on human platelets I: acetylation of a particulate fraction protein. J Clin Invest. 1975; 56: 624.
14. 2 synthase. Nat Struct Biol. 1995; 2: 637.
15. Cryer B., Feldman M.: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998; 104: 413.
16. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenase 1 and 2. Ann Rev Pharmacol Toxicol. 1998; 38: 97.
17. Streppa H.K., Jones C.J., Budsberg S. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood. Am J Vet Res. 2002; 63: 91.
18. Famaey J.P. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibitor by nimesulide P: an overview. Inflamm Res. 1997; 46: 437.
19. Rabasseda X. Nimesulide: a selective cyclooxygenase-2 inhibitor anti-inflammatory drug. Drugs Today. 1996; 32 (suppl. 1): 1.
20. Bernareggi A. Clinical pharmacokinetics and metabolism of nimesulid. Inflammopharmacology. 2001; 9: 81.
21. Bevilacqua M., Vago T., Baldi G., Renesto E., Dallegri F., Norbiato G. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacol. 1994; 268: 415.
22. Capecch P.L., Ceccatelli L., Beermann U., Laghi Pasini F., Perri T. Inhibition of neutrophil function in vitro by nimesulide preliminary evidence of an adenosine - mediated mechanism. Arzneimittel Forschung. 1993; 43: 992.
23. Misra H.P., Fridovich J. The role of superoxide anion in the autooxidation of epinephrine and a simple assay superoxide dismutase. J Biol Chem. 1972; 247: 3170.
24. Sedlak J., Lindsay A. Estimation of total protein bound and nonprotein sulfhydryl group in tissue with Ellman reagent. Anal Biochem. 1968; 26: 192.
25. Little C., O'Brien P. Intracellular GSH-peroxidase with a lipid peroxide substrate. Biophys Res Commun. 1968; 31: 145.
26. Beers R.F., Sizer J. W. Spectrofotomeric method for measuring the breakdown of hydrogen method by catalase, J Biol Chem. 1952; 195: 133.
27. Sies H., Cadenas E. Biological basis of detoxication of oxygen free radicals [w:] Biological basis of detoxication (red.) J. Caqldwell, W.B. Jacoby, Acad. Press, New York, Toronto 1983, 181.
28. Wu R., de Champlain J. Aspirin treatment decreases aortic tissue and cultured aortic smooth muscle cells superoxide production and NAP(P)H oxidase activity in rats. Can Cardiovasc Congess. 2001; Abstracts: 203.
29. Wu R., Lamontagne D., de Champlain J. Antioxidative properties of acetylsalicylic acid on vascular tissue from bormotensive and spontaneously hypertensive rats. Circulation. 2002; 105: 387.
30. Kopff M., Kowalczyk E., Kopff A. Influence of selected cardiological drugs on oxidative status. Polish J Pharmacol. 2004; 56: 265.
31. Cheng I., Zhao C., Amolius A., Gała̧zka M., Doneski L. A hypothesis for the in vivo antioxidant action of salicylic acid. Biometals. 1996; 9: 285.
32. Awtry E.H., Loscalzo J. Aspirin. Circulation. 2000; 101: 1206.
33. Hickey E.J., Raje KR. Reid V.E., Gross S.M., Ray S.D. Diclofenac induced in vivo mnephrotoxicity may involve oxidative stress - mediated massive genomic DNA fragmentation and apoptotic cell death. Free Radic Biol Med. 2001; 31: 139.
34. Hermann M., Camici G., Fratton A. i wsp: Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation. 2003; 108: 2308.
35. El mIDaoui A., Wu R., de Champlaqin J. Prevention of hypertension, hypercalemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rat. J Hypertens. 2002; 20: 1279.
36. Maffei-Facino R., Carini M., Aldini G., Saibene L., Morelli R. Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulid. Arzneimittel Forschung. 1995; 45: 1102.
37. Berilacqua M., Vago T., Baldi G., Renesto E., Dallegri F., Norbiato G. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacol. 1994; 268: 415.
38. Candelario-Jahl E., Leon O.S. Effects of nimesulide on kainite-induced in vitro oxidative damage in rat brain homogenates. BMC Pharmacology. 2003; 3: 7.